4.7 Article

Temperature-induced changes in structural and physicochemical properties of vernix caseosa

Journal

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 128, Issue 2, Pages 292-299

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1038/sj.jid.5701022

Keywords

-

Categories

Ask authors/readers for more resources

The skin of the third trimester fetus and early newborn exhibits a complex, multifunctional, highly hydrated but viscous skin-surface biofilm called vernix caseosa ( VC). During birth, VC undergoes a substantial change from an aqueous and warm surrounding into a gaseous and colder environment postnatally. The aim of this study was to investigate the structural and physicochemical changes in VC, which accompany physiologically relevant variations in environment parameters, such as temperature and humidity. A remarkable difference was observed in water release and uptake properties: dehydration and rehydration processes take place two to four times faster at 37 degrees C than at room temperature (RT). The dehydration was irreversible; rehydration was only possible to a final weight of 55% (37 degrees C) and 46% ( RT) of the pre-desiccation weight. Differential scanning calorimetry showed two different overlapping phase transitions within physiological temperature range. Investigation of the lipid organization by Fourier transform infrared spectroscopy and small-angle X-ray diffraction revealed a more disordered state of lipids at 37 degrees C than at RT, which might explain the faster dehydration and rehydration process at 37 degrees C as well as the changes in thermotropic rheological behavior. In conclusion, we demonstrated that VC properties adjust to the fundamental change from the intrauterine to the post-natal environment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Pharmacology & Pharmacy

Blueprint for mechanistic, data-rich early phase clinical pharmacology studies in dermatology

Robert Rissmann, Matthijs Moerland, Martijn B. A. van Doorn

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)

Article Medicine, Research & Experimental

Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II Trial

Tessa Niemeyer-van der Kolk, Hein van der Wall, Geretta K. Hogendoorn, Rianne Rijneveld, Sascha Luijten, Dirk C. J. G. van Alewijk, Ellen H. A. van den Munckhof, Marieke L. de Kam, Gary L. Feiss, Errol P. Prens, Jacobus Burggraaf, Robert Rissmann, Martijn B. A. van Doorn

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)

Article Medicine, Research & Experimental

Antimicrobial Peptide Omiganan Enhances Interferon Responses to Endosomal Toll-Like Receptor Ligands in Human Peripheral Blood Mononuclear Cells

Hendrika W. Grievink, Silvana M. G. Jirka, Tess D. Woutman, Mascha Schoonakker, Robert Rissmann, Karen E. Malone, Gary Feiss, Matthijs Moerland

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)

Article Pharmacology & Pharmacy

A randomized controlled trial with a delayed-type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man

Mahdi Saghari, Pim Gal, Dimitrios Ziagkos, Jacobus Burggraaf, John F. Powell, Nuala Brennan, Robert Rissmann, Martijn B. A. van Doorn, Matthijs Moerland

Summary: The study demonstrated an increase in anti-KLH antibodies after KLH immunization and a delayed-type hypersensitivity response after intradermal KLH administration. This suggests that the KLH model could serve as an objective tool for studying the pharmacodynamics of T-cell-directed immunomodulatory drugs.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Article Dermatology

Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial

Tessa Niemeyer-van der Kolk, Thomas P. Buters, Lara Krouwels, Jiry Boltjes, Marieke L. de Kam, Hein van der Wall, Dirk C. J. G. van Alewijk, Ellen H. A. van den Munckhof, Martin J. Becker, Gary Feiss, Edwin F. Florencia, Errol P. Prens, Matthijs Moerland, Jacobus Burggraaf, Robert Rissmann, Martijn B. A. van Doorn

Summary: Omiganan restored dysbiosis by reducing Staphylococcus abundance and increasing diversity. However, there was no significant clinical improvement observed.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Article Pharmacology & Pharmacy

Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial

Justin Jacobse, Wouter ten Voorde, Anushka Tandon, Stefan G. Romeijn, Hendrika W. Grievink, Koen van der Maaden, Michiel J. van Esdonk, Dirk Jan A. R. Moes, Floris Loeff, Karien Bloem, Annick de Vries, Theo Rispens, Gertjan Wolbink, Marieke de Kam, Dimitrios Ziagkos, Matthijs Moerland, Wim Jiskoot, Joke Bouwstra, Jacobus Burggraaf, Lenneke Schrier, Robert Rissmann, Rebecca ten Cate

Summary: This study evaluated the feasibility of intradermal administration of adalimumab using hollow microneedles. It was found that intradermal adalimumab injection was perceived as more painful compared to subcutaneous administration, but resulted in higher relative bioavailability and skin reactions. The study also showed similar safety and pharmacokinetic effects between intradermal and subcutaneous administration routes.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Editorial Material Pharmacology & Pharmacy

Commentary on Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies by Sievers et al.

Robert Rissmann, Rob Zuiker

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Article Pharmacology & Pharmacy

Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers

Thomas P. Buters, Pieter W. Hameeteman, Iris M. E. Jansen, Floris C. van Hindevoort, Wouter Ten Voorde, Edwin Florencia, Michelle Osse, Marieke L. de Kam, Hendrika W. Grievink, Mascha Schoonakker, Amit A. Patel, Simon Yona, Derek W. Gilroy, Erik Lubberts, Jeffrey Damman, Gary Feiss, Robert Rissmann, Manon A. A. Jansen, Jacobus Burggraaf, Matthijs Moerland

Summary: This study aimed to characterize the intradermal LPS response in healthy volunteers as a local inflammation model for clinical pharmacology studies. Results showed that intradermal LPS administration induced a visible response, with acute interleukin and tumor necrosis factor protein response followed by different cellular responses. The study suggests that intradermal LPS administration may be a valuable inflammation model for evaluating the pharmacological activity of anti-inflammatory compounds.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers

Thomas P. Buters, Pieter Hameeteman, Iris M. E. Jansen, Floris C. van Hindevoort, Wouter ten Voorde, Hendrika W. Grievink, Mascha Schoonakker, Marieke L. de Kam, Derek W. Gilroy, Gary Feiss, Robert Rissmann, Manon A. A. Jansen, Jacobus Burggraaf, Matthijs Moerland

Summary: In this study, the inhibitory effects of oral and topical corticosteroid treatment on intradermal lipopolysaccharide (LPS) responses were evaluated. The results showed that corticosteroids significantly suppressed the clinical inflammatory response and reduced the secretion of inflammatory mediators. This experimental model is effective in evaluating the effects of anti-inflammatory drugs.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Article Pharmacology & Pharmacy

OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005

Mahdi Saghari, Pim Gal, Sally Gilbert, Martin Yateman, Ben Porter-Brown, Nuala Brennan, Sonia Quaratino, Rosamund Wilson, Hendrika W. Grievink, Erica S. Klaassen, Kirsten R. Bergmann, Jacobus Burggraaf, Martijn B. A. van Doorn, John Powell, Matthijs Moerland, Robert Rissmann

Summary: The safety, tolerability, immunogenicity, and pharmacokinetic profile of anti-OX40L monoclonal antibody KY1005 were evaluated, and its effects on antibody response and skin response were observed. The study found that KY1005 demonstrated an acceptable safety and tolerability profile, showed pharmacological activity, and had potential as a novel pharmacological treatment for immune-mediated disorders.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Article Oncology

Integrin αvβ6 as a Target for Tumor-Specific Imaging of Vulvar Squamous Cell Carcinoma and Adjacent Premalignant Lesions

Bertine W. Huisman, Merve Cankat, Tjalling Bosse, Alexander L. Vahrmeijer, Robert Rissmann, Jacobus Burggraaf, Cornelis F. M. Sier, Mariette I. E. van Poelgeest

Summary: Fluorescence-guided surgery using integrin alpha v beta 6 as a target showed robust discrimination of vulvar tumors and surrounding tissue, suggesting its potential utility in future studies. Immunohistochemistry of membrane proteins identified possible tracers for fluorescence-guided surgery in vulvar (pre)malignancies, emphasizing the need for further evaluation of alpha v beta 6 as a target.

CANCERS (2021)

Review Microbiology

The Human Vulvar Microbiome: A Systematic Review

Lisa Pagan, Roos A. M. Ederveen, Bertine W. Huisman, Jan W. Schoones, Romy D. Zwittink, Frank H. J. Schuren, Robert Rissmann, Jurgen M. J. Piek, Mariette I. E. van Poelgeest

Summary: This systematic review explores the relationship between microbiome and vulvar (pre)malignant disease, revealing differences in vulvar microbiome composition between healthy and diseased states. Although promising, there is limited data with low evidence levels.

MICROORGANISMS (2021)

Review Pharmacology & Pharmacy

A systematic review on disease-drug-drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling

Laura M. de Jong, Sylvia D. Klomp, Nicoline Treijtel, Robert Rissmann, Jesse J. Swen, Martijn L. Manson

Summary: This systematic review aimed to evaluate the risk of disease-drug-drug interactions (DDDIs) caused by immunomodulating drugs and summarize the relevant information in FDA/EMA approved drug labeling. The results showed that the DDDI risk of immunomodulating drugs is specific to target and disease.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Editorial Material Dermatology

Anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic wave

Deepak M. W. Balak, Robert Rissmann

BRITISH JOURNAL OF DERMATOLOGY (2022)

Letter Dermatology

No effect of topical digoxin and furosemide for patients with actinic keratosis

Bertine W. Huisman, Lauren E. H. Nene, Feeke L. L. Linders, Tom K. Gambrah, Tessa Niemeyer van Der Kolk, Marieke L. de Kam, Jan Nico Bouwes Bavinck, Jacobus Burggraaf, Gary Feiss, Robert Rissmann

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

No Data Available